Severe infections (SI) significantly impact on non-relapse mortality after hematopoietic stem cell transplantation (HSCT). We assessed 432 children and adolescents with acute lymphoblastic leukemia (ALL) after total body irradiation based myeloablative HSCT within
the multicenter ALL-BFM-SCT 2003 trial for SI grade 3 or higher according to common terminology criteria for adverse events. A total 172 patients experienced at least one SI. Transplantation from matched unrelated donors (MUD) was associated with any type of SI in the pre-engraftment period (hazard ratio [HR]: 2.57; P < .001), and with any SI between day +30 and + 100 (HR: 2.91; P = .011). Bacterial (HR: 2.24; P = .041) and fungal infections (HR: 4.06; P = .057) occurred more often in the pre-engraftment phase and viral infections more often before day +30 (HR: 2.66; P = .007) or between day +30 and + 100 (HR: 3.89; P = .002) after HSCT from MUD as compared to matched sibling donors.
Chronic GvHD was an independent risk factor for any type of SI after day +100 (HR: 2.57; P < .002). We conclude that allogeneic HSCT from MUD in children and adolescents with pediatric ALL is associated with higher infection rates, which seems attributable to an intensified GvHD prophylaxis including serotherapy and methotrexate.
| INTRODUCTION
Severe infections have remained an important cause of non-relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (HSCT). [1] [2] [3] Infections account for almost 30% of all hospital re-admissions within the first 100 days after HSCT using myeloablative or reduced intensity conditioning. 4, 5 A patients' individual risk for infections after HSCT is influenced by multiple factors including patient characteristics, transplant modalities and post-transplant immune reconstitution. For instance, achieving a sustained neutrophil engraftment is paramount to limit the occurrence of infections caused by gram-positive and gram-negative bacteria or fungi, which are usually observed in the early neutropenic period. 6, 7 Moreover, children and adults transplanted from unrelated donors and those experiencing acute graft-vs-host disease (GvHD) are at higher risk for bacterial and fungal infections. [8] [9] [10] [11] [12] [13] Viral infections or reactivations are typically observed in the postengraftment phase, in particular in patients with delayed T-cell reconstitution or sustained immunosuppression due to acute or chronic GvHD. 7, [14] [15] [16] The most relevant viral infections after HSCT include cytomegalovirus (CMV), adenovirus (AdV) or Ebstein-Barr virus (EBV).
CMV reactivation and -disease is influenced by recipient and donor pre-transplant serostatus and by the presence of CMV-specific T-cells post-transplant. [17] [18] [19] Young age, unrelated or HLA-mismatched donor transplantation, GvHD and delayed T-cell reconstitution are associated with an increased incidence of ADV infections. 20, 21 The incidence of late opportunistic infections occurring beyond day +100 increases after HSCT from unrelated donors and in patients with advanced GvHD. 22 In particular, older patients, individuals with CMV reactivation or patients suffering from severe GvHD are affected by late fungal infections.
23,24
The multicenter ALL-SCT BFM 2003 trial revealed comparable event-free survival and relapse rates in children with acute lymphoblastic leukemia (ALL). This was after transplantation from HLA-matched sibling (MSD) or matched unrelated donors (MUD), defined by HLA match in at least nine of ten loci. However, there was a significantly higher cumulative incidence of NRM after HSCT from MUD, which was primarily attributable to severe infections (16% vs 39%; P < .001). 25 To An approval of the local institutional review board has been obtained at each participating site and the study was performed in accordance with the Declaration of Helsinki. A written informed consent signed by the patients or their legal guardians was obtained before enrolment into the study.
Children in first or subsequent CR of ALL were eligible for study enrolment if an allogeneic HSCT was indicated according to the riskadapted stratification criteria of the Berlin-Frankfurt-Münster (BFM) Study Group. [26] [27] [28] According to the concept of the BFM study group, patients in CR1 were transplanted after minimum of three high-risk (HR) chemotherapy-blocks, aiming to ensure a sound molecular remission with targeted minimal residual disease (MRD) levels below 10E-3.
Patients with standard-risk relapsed ALL were eligible for HSCT after at least five chemotherapy blocks, and patients with high-risk relapses after at least three blocks, according to the BFM concept, aiming MRD levels below 10E-3 before HSCT respectively. Detailed information on study design, criteria for patient and donor selection and conditioning regimens has been published previously.
25
The GvHD-prophylaxis for patients transplanted from MSD consisted of cyclosporin A (CsA) only, starting at day −1, and given at a 
| Definition of infection-related complications/microbiological methods
The cohort was evaluated for severe infections (SI) graded III or higher, according to the common terminology criteria for adverse events (CTCAE). 29 All reported SI were then analyzed for the respective contributing pathogens, and grouped according to their appearance as follows: Infections occurring within the first 30 days after HSCT, infections between day +30 and day +100, or infections beyond day +100 after HSCT.
In symptomatic patients, an infection was classified as confirmed when at least one positive microbiological testing result was obtained.
Positive results from surveillance cultures due to colonization or contamination in otherwise asymptomatic patients and asymptomatic viremias were not considered. Only the first infection of the respective pathogen in a given patient within the pre-defined time periods was considered for the calculation of transplant outcomes, per previous publications. 22, 30 Also, transplant-related variables considered relevant to impact on infection risk were retrieved from our database, and put in the univariate and multivariate analysis models. 
| Supportive care and infection prophylaxis
Detailed information on supportive care recommendations is provided elsewhere. 25 In brief, all patients were nursed in rooms with reverse isolation and high-efficiency particulate air filters during the neutropenic period, and received a low bacterial diet. Prophylaxis against pneumocystis jirovecii primarily consisted of trimethoprim/sulfamethoxazole starting at day +28.
All prophylactic therapies were carried on until the immunosuppression was stopped or adequate immunologic recovery was reached.
The institution and choice of empirical first-line treatment of febrile neutropenia with broad-spectrum antibiotics was left at the discretion of the attending physicians and was carried out according to local center policies.
| Statistical analysis
For non-time to event variables, the chi-Square and Fisher's exact test were used to compare groups of categorical variables. Wilcoxon ranksum test (Kruskal-Wallis test for more than two populations) was used for continuous variables. The cumulative incidence (CI) of infection was analyzed for the whole cohort of patients. This was also done separately for the time periods before day +30, between day +30 and + 100, and beyond day +100 after HSCT, and for the different types of infections. The CI was calculated for first episode of infection of respective type and for the respective time period. The univariate analysis was conducted according to the method of Kalbfleisch and Prentice, 31 groups were compared using the Gray test. 32 The role of risk factors for the CI of infections was further analyzed in a multivariate proportional sub-distribution hazards model by Fine and Gray for censored data subject to competing risks. 33 Relapse and death without infection were defined as competing events. Acute and chronic
GvHD were considered time dependent, while for non-relapse mortality (NRM), relapses and secondary malignancies were considered competing events. All P values below .05 were considered significant. The statistical analyses were performed by means of the SAS version 9.4
(SAS Institute, Cary, NC).
| RESULTS
In total, 432 children and adolescents with ALL in first (n = 233) or second (n = 199) CR, and available data on infection-related toxicity 
| Cumulative incidences of infections at predefined time periods
Among 172 of 432 patients (40%) with at least one single SI reported, 464 SI were registered in total, including bacteria in 122 (26%) cases, viruses in 274 (59%), fungi in 29 cases (6%) and protozoa in one case (0.2%) respectively (Table S1 ). In 38 cases (8%) a pathogen was not confirmed despite an overt clinical presentation suggesting a SI. The majority of SI (56%) was classified as systemic infection due to positive testing results from blood samples. In cases of severe localized infections, the affected sites included the gastrointestinal tract (26%), the urinary tract (17%), the lungs (12%), skin or soft tissues (11%), the central nervous system (4%) or various other sites (30%). The median time to the first SI caused by any pathogen was 19 days (range: 0-1441). range: 3-405). Figure S1B 3.3 | Impact of transplant-specific parameters on infections after HSCT: Univariate and multivariate analysis
The donor type correlated significantly with the incidence of SI. Transplantation from MSD, compared to MUD, was associated with lower rates for any SI occurring within the first 30 days (16% vs 32%; P < .001), or between day +30 and day +100 (6% vs 23%; P < .001), while SI beyond day +100 were not different among the donor groups. Comparable results were obtained for different pathogens. The infection incidences within 30 days after HSCT were lower after HSCT from MSD, compared to the MUD group (8% vs 15%
(P = .057) for bacterial infections, 8% vs 18% (P < .005) for viral and 2% vs 6% (P = .073) for fungal infections). The incidence of viral infections in the post-engraftment period was significantly lower in the MSD group (5% vs 19%; P < .001).
F I G U R E 1 Cumulative incidences (CI) of the first severe infection and CI of death due to infection at day +30, +100 and 1 year after transplant for any type of infections F I G U R E 2 Cumulative incidences (CI) of bacterial, fungal and viral infections at day +30, +100 and 1 year after transplant Serotherapy with anti-thymocyte globulin (ATG) as administered for HSCT from MUD was associated with higher overall infection rates within the first 30 days (31% vs 17%; P = .002), and between day +30 and + 100 (23% vs 7%; P < .001), as compared to transplantation without ATG in the MSD group. Similar results were found for bacterial (14% vs 8%, P = .113), viral (18% vs 9%, P = .001) and fungal infections (6% vs 2%, P = .072) within the first 30 days. Between day +30 and day +100, significantly more viral infections were observed in the serotherapy group (19% vs 6%; P = .001).
The ALL phenotype, the remission status, recipient age, donor/recipient gender constellation, the graft type, graft CD34+ content, CMV-or EBV donor/recipient serostatus, or the time interval from diagnosis to HSCT, did not significantly impact infection rates for the defined time periods. for infections after day +100).
Chronic GvHD was an independent risk factor for any SI beyond day +100 (HR: 2.57; 95% CI: 1.43-4.63; P = .002), and we found a non-significant trend for any SI occurring between day +30
and + 100 in patients with acute GvHD grade 3 or 4 (HR: 1.56; 95% CI: 0.91-2.69; P = .108). The multivariate analysis is shown in 
| Lethal infections/impact on non-relapse mortality
Eleven patients died due to severe infections, one of them after HSCT from MSD and 10 after MUD transplantation. The reported primary causes of death were bacteria in three cases, viruses in seven cases, and a fungal pathogen in one case, respectively. Lethal infections occurred within the pre-engraftment phase in six cases, between day +30 and + 100 in four cases, and after day +100 in one patient.
The calculated 1-year cumulative incidence of death due to infection was 0.03 ± 0.01 (Figure 1 ).
| DISCUSSION
Severe infections (SI) are encountered in up to 60% of patients receiving HSCT. They remain a major cause of non-relapse mortality after allografting for malignant and non-malignant diseases in adults. accounting for 42% of all GP infections, were the most frequent isolates in our cohort, in line with previous observations. 9,12,37 However, a contamination or colonization seems conceivable in several of these cases.
Gram-negative infections were primarily caused by Escherichia spp. or Pseudomonas spp., accounting for approximately 20% of all GN isolates each. Other investigators reported infection rates up to 37% for E. coli and 26% for Pseudomonas. 22, 35, 37 Of note, our cohort did not routinely receive prophylactic fluoroquinolones, which was a common practice among many adult transplant centers during the last decade, to lower the burden of GN strains. 38 Severe kinds of bacterial infections accounted for 27% of all lethal infections, and occurred within the first 100 days in most cases.
The early neutropenic period is not only critical for the development of bacterial but also for fungal infections, although a shift towards later fungal infections has been reported during recent years. 7, 11, 39, 40 The CI of the first fungal SI in our cohort was 0.04 ± 0.01 at day +30, 0.05 ± 0.01 at day+100 and 0.06 ± 0.01 1 year after HSCT. The majority of severe fungal infections were caused by Aspergillus spp. (48%) and Candida (38%), both primarily observed in the pre-engraftment phase.
Other fungal pathogens, such as mucormycetes, were rarely detected.
Infections by Aspergillus spp. were fatal in 7% of reported cases. Altogether, fungal infections accounted for 10% of the eleven reported fatalities, which is in contrast to Srinivasan et al., who reported more than 50% of all fatal infections being caused by molds in a similar pediatric cohort. 22 The comparably low overall rate of invasive fungal infections in our study might have various reasons. Most centers provided a primary antifungal prophylaxis until adequate immune reconstitution was reached.
The immunosuppression in patients without acute GvHD was tapered as soon as day +60 on, to minimize the relapse risk in our cohort, which might have prevented late fungal infections. Also, the low overall acute GvHD rates within the study population (acute GvHD grade 2 or 3: per se is associated with invasive aspergillosis, primarily due to substantial immunosuppression including corticosteroids.
11
Systemic viral infections have been reported in up to 60% of children after HSCT. 30 Viremia is most frequently detected after the engraftment period. 41 Although not exclusively confined to the postengraftment period, viral infections in our cohort were mainly observed during this phase. As shown in Figure S1B , severe EBV and CMV infections usually occurred after day +30, whereas AdV infec- Methotrexate is well known to interfere with granulocyte recovery after HSCT. 43 A prolonged neutropenia increases the risk, especially for severe bacterial or fungal infections. 7 Patients transplanted from MSD recovered their neutrophils significantly faster, compared to recipients of MUD grafts, as reported previously. 44 This might have influenced infection rates in the pre-engraftment period after HSCT from unrelated donors. Both, bacterial and fungal infections were observed more often after HSCT from MUD.
In-vivo T-cell depletion with ATG additionally seems to increase the infection risk. It has been demonstrated, that ATG impairs the T-cell reconstitution, 45, 46 which in turn might facilitate virus reactivations. 47 In line, significantly more viral infections were observed before day +30, or between day +30 and +100 after HSCT from MUD, compared to transplantation from MSD, who did not receive ATG. Although it is impossible for our cohort to prove that the observed effect in patients transplanted from MUD is directly related to the administration of ATG, an association seems at least conceivable. Unfortunately, data on T-cell immune reconstitution is not available.
Patients with GvHD often require an intensified immunosuppression, including high-dose corticosteroids, which make them susceptible to opportunistic infections. 48, 49 Children in our cohort with acute GvHD grade 3 or 4, had a non-significant trend towards SI occurring beyond day +30, as reported by others. 22, 50, 51 Moreover, children with chronic GvHD particularly were at risk for any type of T A B L E 2 (Continued) SI occurring beyond day +100. That confirms the data by Srinivasan, who identified chronic GvHD as an independent risk factor for bacterial and fungal infections beyond day +100 after HSCT in a similar cohort. 22 We are aware that our study has several limitations, which are the heterogeneous practice for antimicrobial prophylaxis, pre-emptive or empiric treatment of infections, the lack of standardized microbiological testing methods for all participating centers, and missing information on antimicrobial resistance of pathogens. Detailed information on pre-transplant chemotherapy, or on asymptomatic viral reactivations after HSCT, was not available. Furthermore, the cohort was too small for a thorough subgroup analysis.
In conclusion, our study confirms the correlation between donor type and infection rates in a cohort of 432 children and adolescents, after TBI-based myeloablative HSCT for ALL. Transplantation from MUD was associated with an increased risk for any type of SI in the pre-engraftment period, and for viruses between day +30 and + 100 after HSCT. This could be explained by an intensified GvHD prophylaxis consisting of serotherapy with ATG and administration of methotrexate for recipients of MUD transplants.
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